Patents by Inventor Takayoshi Nagasaki

Takayoshi Nagasaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8933117
    Abstract: To provide potassium salts of substituted cycloalkene derivatives, which suppress the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, and crystals thereof. The present invention provides potassium (2-chloro-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide and potassium (2-bromo-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide, each of which suppresses the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, crystals thereof, and a pharmaceutical containing any of the same, and a prophylactic and/or therapeutic agent for sepsis containing any of the same.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: January 13, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Nobuyuki Ohkawa, Kouki Iida, Takayoshi Nagasaki
  • Publication number: 20140073689
    Abstract: To provide potassium salts of substituted pyrrolidine derivatives, which suppress the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, and crystals thereof. The present invention provides potassium(2-chloro-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide and potassium(2-bromo-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide, each of which suppresses the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, crystals thereof, and a pharmaceutical containing any of the same, and a prophylactic and/or therapeutic agent for sepsis containing any of the same.
    Type: Application
    Filed: September 22, 2011
    Publication date: March 13, 2014
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Nobuyuki Ohkawa, Kouki Iida, Takayoshi Nagasaki
  • Publication number: 20130178521
    Abstract: To provide potassium salts of substituted pyrrolidine derivatives, which suppress the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, and crystals thereof. The present invention provides potassium(2-chloro-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide and potassium(2-bromo-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide, each of which suppresses the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, crystals thereof, and a pharmaceutical containing any of the same, and a prophylactic and/or therapeutic agent for sepsis containing any of the same.
    Type: Application
    Filed: September 22, 2011
    Publication date: July 11, 2013
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Nobuyuki Ohkawa, Kouki Iida, Takayoshi Nagasaki
  • Patent number: 7935835
    Abstract: A compound of formula (I) Wherein X, Y, ring A, ring B, l, m, R1, R2, R4 and R5 are as defined herein, to supress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-?, pharmacologically acceptable salts therefor, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: May 3, 2011
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tomio Kimura, Nobuyuki Ohkawa, Takayoshi Nagasaki, Atsuhiro Sugidachi, Osamu Ando
  • Publication number: 20090233952
    Abstract: [Object] To provide a substituted cycloalkene derivative having an action to suppress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-?, pharmacologically acceptable salts therefor, a medicament containing them as an active ingredient, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation.
    Type: Application
    Filed: September 13, 2006
    Publication date: September 17, 2009
    Inventors: Tomio Kimura, Nobuyuki Ohkawa, Takayoshi Nagasaki, Atsuhiro Sugidachi, Osamu Ando
  • Publication number: 20070049620
    Abstract: A cyclic tertiary amine compound which is capable of inhibiting the production of inflammatory cytoines. The compound having a structure represented by the following formula (I): wherein A represents an optionally substituted trivalent group which is benzene, pyrimidine, pyrrole, pyridine, pyridazine, furan, thiopene, pyrazole, imidazole, isoxazole or isothiazole; R1 represents an aryl or a heteroaryl group, which is unsubstituted or substituted; R2 represents a heteroaryl group which is unsubtituted or substituted; and R3 represents a cyclic tertiary amino group, or a pharmacologically acceptable salt of the compound.
    Type: Application
    Filed: December 12, 2005
    Publication date: March 1, 2007
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Tomio Kimura, Nobuyuki Ohkawa, Akira Nakao, Takayoshi Nagasaki, Takaichi Shimozato
  • Patent number: 7122666
    Abstract: Compounds having activity against production of an inflammatory cytokine of formula (I)?: A? is pyrrole; R1? is phenyl or naphthyl; R2? is pyridyl or pyrimidinyl; R3? is (IIa)?, (IIb)? or (IIc)?: m? is 1; E? is nitrogen; D? is >C(R5?)—, R5? is hydrogen, Substituent ?? or Substituent ??; B? is nitrogen-containing 5-membered heterocyclic; R4? is 1 to 3 substituents from Substituent ??, Substituent ?? and Substituent ??; R1? and R3? are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R2?; Substituent ?? is hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NRa?Rb?; Ra? and Rb? are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or Ra? and Rb? with the nitrogen atom form a heterocyclyl; Substituent ?? is alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent ?? is oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: October 17, 2006
    Assignee: Sankyo Company, Limited
    Inventors: Tomio Kimura, Akira Nakao, Nobuyuki Ohkawa, Takayoshi Nagasaki, Takanori Yamazaki
  • Publication number: 20050283006
    Abstract: Compounds having activity against production of inflammatory cytokines of formula (I)?: A? is pyrrole; R1? is aryl or heteroaryl; R2? is heteroaryl having at least one nitrogen atom; R3? is (IIa)?, (IIb)? or (IIc)?: m? is 1 or 2; one of D? and E? is nitrogen and the other is >C(R5?)—, R5? is hydrogen, Substituent ?? or Substituent ??; B? is nitrogen-containing 4- to 7-membered heterocyclic; R4? is 1 to 3 substituents from Substituent ??, Substituent ?? and Substituent ??; R1? and R3? are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R2?; Substituent ??: hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NRa?Rb?; Ra? and Rb? are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or Ra? and Rb? with the nitrogen atom form a heterocyclyl; Substituent ??: alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent ??: oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkyl
    Type: Application
    Filed: April 10, 2003
    Publication date: December 22, 2005
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Tomio Kimura, Kazumasa Aoki, Akira Nakao, Shigeru Ushiyama, Takaichi Shimozato, Nobuyuki Ohkawa, Takayoshi Nagasaki, Takanori Yamazaki
  • Publication number: 20050159444
    Abstract: A bicyclic unsaturated tertiary amine compound capable of inhibiting the production of inflammatory cytokines. The compound has the following formula (I): wherein A represents pyrrole or pyrazole, R1 represents an aryl group or a heteroaryl group which may be substituted, R2 represents a heteroaryl group which may be substituted, and R3 represents an indolizine group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
    Type: Application
    Filed: January 19, 2005
    Publication date: July 21, 2005
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Tomio Kimura, Nobuyuki Ohkawa, Kazumasa Aoki, Akira Nakao, Takayoshi Nagasaki
  • Publication number: 20040054173
    Abstract: Compounds having activity against production of an inflammatory cytokine of formula (I)′: 1
    Type: Application
    Filed: January 30, 2003
    Publication date: March 18, 2004
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Tomio Kimura, Kazumasa Aoki, Akira Nakao, Shigeru Ushiyama, Takaichi Shimozato, Nobuyuki Ohkawa, Takayoshi Nagasaki, Takanori Yamazaki
  • Patent number: RE43858
    Abstract: A compound of formula (I) Wherein X, Y, ring A, ring B, l, m, R1, R2, R4 and R5 are as defined herein, to supress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-?, pharmacologically acceptable salts therefor, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: December 11, 2012
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tomio Kimura, Nobuyuki Ohkawa, Takayoshi Nagasaki, Atsuhiro Sugidachi, Osamu Ando